Sfunga Therapeutics is now Elion Therapeutics
Transforming the treatment of invasive fungal infections
Elion Therapeutics is a cutting-edge biotechnology company dedicated to transforming the treatment of life-threatening fungal infections using a novel approach that’s rooted in structural chemistry. Elion was founded with the belief that mechanistic insights enable targeted optimizations of natural products. Today, Elion is advancing the first polyene antifungal rationally designed to mitigate toxicities and increase safety.
Our lead compound, SF001, was designed to bind specifically to fungal ergosterol, thereby mitigating the toxicities associated with binding to mammalian cholesterol. SF001 is currently in Phase 1 clinical studies.
Our seasoned leadership team brings more than 200 years of collective expertise in antifungal drug development. The team is led by cofounder Kieren Marr, MD, MBA, FIDSA, and backed by Deerfield Management Company—an investment firm dedicated to advancing healthcare through information, investment, and philanthropy.